Short ADCTA short at 6.05 to 5.03 with the necessary risk management will bring a 16.90% returnShortby KyleUKMay 6, 20240
trading it to $30With an ADC platform validated by the FDA approval of ZYNLONTA® and a deep understanding of the oncology treatment landscape, ADCT is working to address significant unmet medical needs and improve outcomes for those with difficult-to-treat hematological cancers and solid tumors. Nby KhanhC.HoangAug 15, 20220
ADCT ready to go- Price break trendline, break price cluster - RSI overbought - MACD crosses upNLongby hernfatakDec 27, 20200
ADCT: Inverse Head and Shoulders. ADCT broke inverse H&S in NOV. 20. At this moment should be only testing resistance. Stop loss at $32.50 and target is $42.00 NLongby jlope125Nov 30, 20200
